🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with estimates suggesting over 82 million infections per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in the same week. This medication, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This approval represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

According to data detailed in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which combines an injection and a pill. The trial involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Having a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is considered vital to reduce the burden of the illness for patients and to stop the proliferation of untreatable gonorrhoea globally.